– Company appoints
internationally renowned clinician, Martin
S. Tallman, MD as inaugural clinician member
HOUSTON, May 1, 2024 /PRNewswire/ -- Moleculin Biotech,
Inc., (Nasdaq: MBRX) (Moleculin or the Company), a
clinical stage pharmaceutical company with a broad portfolio of
drug candidates targeting hard-to-treat tumors and viruses, today
announced the formation of its Annamycin Scientific Advisory Board
and inaugural appointment of Dr. Martin
Tallman.
Dr. Tallman is an internationally renowned clinical
investigator whose discoveries have fueled the progress of
leukemia-targeting therapies, most recently with the Robert H.
Lurie Comprehensive Cancer Center of Northwestern University. Prior to his role at Lurie
Cancer Center where he focused on the management and development of
new treatments for patients with both acute and chronic leukemias,
he was at Memorial Sloan Kettering Cancer Center where he served as
chief of the Leukemia Service and Professor of Medicine at the
Weill Cornell Medical College in New
York. He was the president of the American Society of
Hematology (ASH) in 2021, chaired the Leukemia Committee of the
Eastern Cooperative Oncology Group (ECOG) for 16 years, and served
as immediate past chair of the National Comprehensive Cancer
Network (NCCN) Acute Myeloid Leukemia Panel. Dr. Tallman previously
served at Northwestern University
Feinberg School of Medicine as Professor of Medicine prior to his
appointment at Sloan Kettering.
Walter Klemp, Chairman and Chief
Executive Officer of Moleculin commented, "We continue to be
encouraged by the growing body of data Annamycin has demonstrated
across our ongoing development programs. As we continue on our
pathway forward, we are pleased to bolster our Annamycin
development programs with the formation of this Scientific Advisory
Board and add the internationally-renowned knowledge and expertise
of Dr. Tallman. We are committed to advancing our clinical and
regulatory strategies toward our next phase of development for
Annamycin."
Dr. Tallman added, "The latest preliminary AML data suggest that
Annamycin could result in a promising new the treatment for AML. I
am excited to work alongside the Moleculin team to continue
advancing its development and further explore its potential to
address these areas of significant unmet need."
Annamycin currently has Fast Track Status and Orphan Drug
Designation from the U.S. Food and Drug Administration for the
treatment of relapsed or refractory AML and Orphan Drug Designation
for the treatment of STS lung mets, in addition to Orphan Drug
Designation from the European Medicines Agency for the treatment of
AML.
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a clinical stage pharmaceutical
company with a growing pipeline, including Phase 2 clinical
programs, for hard-to-treat tumors and viruses. The Company's lead
program, Annamycin is a next-generation anthracycline designed to
avoid multidrug resistance mechanisms with little to no
cardiotoxicity. Annamycin is currently in development for the
treatment of relapsed or refractory acute myeloid leukemia (AML)
and soft tissue sarcoma (STS) lung metastases. All interim and
preliminary data discussed above is subject to change.
Additionally, the Company is developing WP1066, an
Immune/Transcription Modulator capable of inhibiting p-STAT3 and
other oncogenic transcription factors while also stimulating a
natural immune response, targeting brain tumors, pancreatic and
other cancers, and WP1220, an analog to WP1066, for the topical
treatment of cutaneous T-cell lymphoma. Moleculin is also engaged
in the development of a portfolio of antimetabolites, including
WP1122 for the potential treatment of viruses, as well as cancer
indications including brain tumors, pancreatic and other
cancers.
For more information about the Company, please
visit www.moleculin.com and connect on Twitter,
LinkedIn and Facebook.
Forward-Looking Statements
Some of the statements in this release are forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, which involve
risks and uncertainties. Forward-looking statements in this press
release include, without limitation, the timing of the commencement
of a pivotal registration study of Annamycin as a
2nd line therapy in AML before year end. Although
Moleculin believes that the expectations reflected in such
forward-looking statements are reasonable as of the date made,
expectations may prove to have been materially different from the
results expressed or implied by such forward-looking statements.
Moleculin has attempted to identify forward-looking statements by
terminology including 'believes,' 'estimates,' 'anticipates,'
'expects,' 'plans,' 'projects,' 'intends,' 'potential,' 'may,'
'could,' 'might,' 'will,' 'should,' 'approximately' or other words
that convey uncertainty of future events or outcomes to identify
these forward-looking statements. These statements are only
predictions and involve known and unknown risks, uncertainties, and
other factors, including those discussed under Item 1A. "Risk
Factors" in our most recently filed Form 10-K filed with the
Securities and Exchange Commission (SEC) and updated from time to
time in our Form 10-Q filings and in our other public filings with
the SEC. Any forward-looking statements contained in this release
speak only as of its date. We undertake no obligation to update any
forward-looking statements contained in this release to reflect
events or circumstances occurring after its date or to reflect the
occurrence of unanticipated events.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
MBRX@jtcir.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/moleculin-announces-formation-of-scientific-advisory-board-to-support-development-of-annamycin-302132955.html
SOURCE Moleculin Biotech, Inc.